Clinical development of new treatments for diabetic macular oedema

REFERENCES

• Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol 2009; 54: 1–32.
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Moss SE, Davis MD, Demets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IV. Diabetic macular edema. Ophthalmology 1984; 91: 1464–1474.
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long‐term incidence of macular edema. Ophthalmology 1995; 102: 7–16.
   PubMed Web of Science ®Google Scholar
• The effect of intensive treatment of diabetes on the development and progression of long‐term complications in insulin‐dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977–986.
   PubMed Web of Science ®Google Scholar
• Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: 703–713. (Erratum in BMJ 1999; 318: 29.)
   PubMed Web of Science ®Google Scholar
• Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985; 103: 1796–1806.
   PubMed Web of Science ®Google Scholar
• Aroca PR, Salvat M, Fernández J, Méndez I. Risk factors for diffuse and focal macular edema. J Diabetes Complications 2004; 18: 211–215.
   PubMed Web of Science ®Google Scholar
• Bresnick GH. Diabetic maculopathy. A critical review highlighting diffuse macular edema. Ophthalmology 1983; 90: 1301–3017.
   PubMed Web of Science ®Google Scholar
• Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no. 19. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol 1995; 113: 1144–1155.
   PubMed Web of Science ®Google Scholar
• Gandorfer A. Diffuse diabetic macular edema: pathology and implications for surgery. Dev Ophthalmol 2007; 39: 88–95.
   PubMedGoogle Scholar
• Chen J, Lee L. Clinical applications and new developments of optical coherence tomography: an evidence‐based review. Clin Exp Optom 2007; 90: 317–335.
   PubMed Web of Science ®Google Scholar
• Panozzo G, Gusson E, Parolini B, Mercanti A. Role of OCT in the diagnosis and follow up of diabetic macular edema. Semin Ophthalmol 2003; 18: 74–81.
   PubMedGoogle Scholar
• Goebel W, Franke R. Retinal thickness in diabetic retinopathy: comparison of optical coherence tomography, the retinal thickness analyzer, and fundus photography. Retina 2006; 26: 49–57.
   PubMed Web of Science ®Google Scholar
• Goatman KA. A reference standard for the measurement of macular oedema. Br J Ophthalmol 2006; 90: 1197–1202.
   PubMed Web of Science ®Google Scholar
• Schaudig UH, Glaefke C, Scholz F, Richard G. Optical coherence tomography for retinal thickness measurement in diabetic patients without clinically significant macular edema. Ophthalmic Surg Lasers 2000; 31: 182–186.
   Google Scholar
• Chan A, Duker JS. A standardized method for reporting changes in macular thickening using optical coherence tomography. Arch Ophthalmol 2005; 123: 939–943.
   Google Scholar
• Fraser‐bell S, Kaines A, Hykin PG. Update on treatments for diabetic macular edema. Curr Opin Ophthalmol 2008; 19: 185–189.
   PubMed Web of Science ®Google Scholar
• Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular edema. Long‐term visual results. Ophthalmology 1991; 98: 1594–1602.
   PubMed Web of Science ®Google Scholar
• Hudson C, Flanagan JG, Turner GS, Chen HC, Young LB, Mcleod D. Influence of laser photocoagulation for clinically significant diabetic macular oedema (DMO) on short‐wavelength and conventional automated perimetry. Diabetologia 1998; 41: 1283–1292.
   PubMed Web of Science ®Google Scholar
• Rutledge BK, Wallow IH, Poulsen GL. Sub‐pigment epithelial membranes after photocoagulation for diabetic macular edema. Arch Ophthalmol 1993; 111: 608–613.
   PubMedGoogle Scholar
• Schatz H, Madeira D, Mcdonald HR, Johnson RN. Progressive enlargement of laser scars following grid laser photocoagulation for diffuse diabetic macular edema. Arch Ophthalmol 1991; 109: 1549–1551.
   PubMedGoogle Scholar
• Jonas JB, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 2001; 132: 425–427.
   PubMed Web of Science ®Google Scholar
• Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, Baumal C. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002; 109: 920–927.
   PubMed Web of Science ®Google Scholar
• Massin P, Audren F, Haouchine B, Erginay A, Bergmann J‐F, Benosman R, Caulin C et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 2004; 111: 218–224.
   PubMed Web of Science ®Google Scholar
• Sutter FKP, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three‐month efficacy and safety results of a prospective, randomized, double‐masked, placebo‐controlled clinical trial. Ophthalmology 2004; 111: 2044–2049.
   PubMed Web of Science ®Google Scholar
• Karacorlu M, Ozdemir H, Karacorlu S, Alacali N, Mudun B, Burumcek E. Intravitreal triamcinolone as a primary therapy in diabetic macular oedema. Eye 2005; 19: 382–386.
   PubMed Web of Science ®Google Scholar
• Gillies MC, Sutter FKP, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: two‐year results of a double‐masked, placebo‐controlled, randomized clinical trial. Ophthalmology 2006; 113: 1533–1538.
   PubMed Web of Science ®Google Scholar
• Sears JE, Hoppe G. Triamcinolone acetonide destabilizes VEGF mRNA in Müller cells under continuous cobalt stimulation. Invest Ophthalmol Vis Sci 2005; 46: 4336–4341.
   PubMed Web of Science ®Google Scholar
• Gardner TW, Antonetti DA, Barber AJ, Lanoue KF, Levison SW. Diabetic retinopathy: more than meets the eye. Surv Ophthalmol 2002; 47 (Suppl 2): S253–S262.
   Google Scholar
• Diabetic Retinopathy Clinical Research N. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008; 115: 1447–1449.
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network (DRCR.net), Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR et al. Three‐year follow‐up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009; 127: 245–251.
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117: 1064–1077.e35.
   PubMed Web of Science ®Google Scholar
• Hauser D, Bukelman A, Pokroy R, Katz H, Len A, Thein R, Parness‐yossifon R, Pollack A. Intravitreal triamcinolone for diabetic macular edema: comparison of 1, 2, and 4-mg. Retina 2008; 28: 825–830.
   PubMed Web of Science ®Google Scholar
• Audren F, Lecleire‐collet A, Erginay A, Haouchine B, Benosman R, Bergmann J‐F, Gaudric A, Massin P. Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4-mg vs 2-mg. Am J Ophthalmol 2006; 142: 794–799.
   PubMed Web of Science ®Google Scholar
• Lam DSC, Chan CK, Mohamed S, Lai TY, Li KK, Li PS, Tsang C‐W, Chan WM et al. A prospective randomised trial of different doses of intravitreal triamcinolone for diabetic macular oedema. Br J Ophthalmol 2007; 91: 199–203.
   PubMed Web of Science ®Google Scholar
• Quiram PA, Gonzales CR, Schwartz SD. Severe steroid‐induced glaucoma following intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 2006; 141: 580–582.
   PubMed Web of Science ®Google Scholar
• Gillies MC, Islam FMA, Larsson J, Pasadhika S, Gaston C, Zhu M, Wong TY. Triamcinolone‐induced cataract in eyes with diabetic macular oedema: 3‐year prospective data from a randomized clinical trial. [Erratum in Clin Experiment Ophthalmol 2010; 38: 741]. Clin Experiment Ophthalmol 2010; 38: 605–612.
   PubMed Web of Science ®Google Scholar
• Gillies MC, Simpson JM, Luo W, Penfold P, Hunyor AB, Chua W, Mitchell P et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age‐related macular degeneration: one‐year results. Arch Ophthalmol 2003; 121: 667–673.
   PubMed Web of Science ®Google Scholar
• Sutter F, Simpson J, Gillies M. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three month efficacy and safety results of a prospective, randomized, double‐masked, placebo‐controlled clinical trial. Ophthalmology 2004; 111: 2044–2049.
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network. Randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008; 115: 1447–1459.
   PubMed Web of Science ®Google Scholar
• Jonas J, Degenring R, Kreissig I, Akkoyun I. Safety of intravitreal high‐dose reinjections of triamcinolone acetonide. Am J Ophthalmol 2004; 138: 1054–1055.
   PubMed Web of Science ®Google Scholar
• Scott I, Flynn H. Reducing the risk of endophthalmitis following intravitreal injections. Retina 2007; 27: 10–12.
   PubMed Web of Science ®Google Scholar
• Lam DS, Chan CK, Mohamed S, Lai TY, Lee VY, Lai WW, Fan DS, Chan WM. Phacoemulsification with intravitreal triamcinolone in patients with cataract and coexisting diabetic macular oedema: a 6‐month prospective pilot study. Eye 2005; 19: 885–890.
   PubMed Web of Science ®Google Scholar
• Jonas JB, Kreissig I, Degenring RF. Cataract surgery after intravitreal injection of triamcinolone acetonide. Eye 2004; 18: 361–364.
   PubMed Web of Science ®Google Scholar
• Massin P, Audren F, Haouchine B, Erginay A, Bergmann J‐F, Benosman R, Caulin C et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 2004; 111: 218–224.
   PubMed Web of Science ®Google Scholar
• Chan C, Mohamed S, Shanmugam M, Tsang C, Lai T, Lam D. Decreasing efficacy of repeated intravitreal triamcinolone injections in diabetic macular oedema. Br J Ophthalmol 2006; 90: 1137–1141.
   Web of Science ®Google Scholar
• Gillies MC, Islam FM, Zhu M, Larsson J, Wong T. Efficacy and safety of multiple intravitreal triamcinolone injections for refractory diabetic macular oedema. Br J Ophthalmol 2007; 91: 1323–1326.
   PubMed Web of Science ®Google Scholar
• Avitabile T, Longo A, Reibaldi A. Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol 2005; 140: 695–702.
   PubMed Web of Science ®Google Scholar
• Lam DS, Chan CK, Mohamed S, Lai TY, Lee VY, Liu DT, Li KK et al. Intravitreal triamcinolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema: six‐month outcomes. Ophthalmology 2007; 114: 2162–2167.
   PubMed Web of Science ®Google Scholar
• Kang SW, Sa HS, Cho HY, Kim JI. Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema. Arch Ophthalmol 2006; 124: 653–658.
   PubMed Web of Science ®Google Scholar
• Gillies MC, Mcallister IL, Zhu M, Wong W, Louis D, Arnold JJ, Wong TY. Intravitreal triamcinolone prior to laser treatment of diabetic macular edema: 24‐month results of a randomized controlled trial. Ophthalmology 2011; 118: 866–872.
   PubMed Web of Science ®Google Scholar
• Pearson PA, Comstock TL, Ip M, Callanan D, Morse LS, Ashton P, Levy B et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3‐year multicenter, randomized, controlled clinical trial. Ophthalmology 2011; 118: 1580–1587.
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Brown DM, Pearson A, Ciulla T, Boyer D, Holz FG, Tolentino M et al. Long‐term benefit of sustained‐delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 2011; 118: 626–635.e2.
   PubMed Web of Science ®Google Scholar
• Haller JA, Kuppermann BD, Blumenkranz MS, Williams GA, Weinberg DV, Chou C, Whitcup SM et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010; 128: 289–296.
   PubMed Web of Science ®Google Scholar
• Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, Whitcup SM et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007; 125: 309–317.
   PubMed Web of Science ®Google Scholar
• Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480–1487.
   PubMed Web of Science ®Google Scholar
• Derevjanik NL, Vinores SA, Xiao W‐H, Mori K, Turon T, Hudish T, Dong S et al. Quantitative assessment of the integrity of the blood‐retinal barrier in mice. Invest Ophthalmol Vis Sci 2002; 43: 2462–2467.
   PubMed Web of Science ®Google Scholar
• Ozaki H, Hayashi H, Vinores SA, Moromizato Y, Campochiaro PA, Oshima K. Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood‐retinal barrier in rabbits and primates. Exp Eye Res 1997; 64: 505–517.
   PubMed Web of Science ®Google Scholar
• Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina 2005; 25: 111–118.
   PubMed Web of Science ®Google Scholar
• Chapman JA, Beckey C. Pegaptanib: a novel approach to ocular neovascularization. Ann Pharmacother 2006; 40: 1322–1326.
   Web of Science ®Google Scholar
• Cunningham ET Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'amico DJ, Goldbaum M et al. A phase II randomized double‐masked trial of pegaptanib, an anti‐vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005; 112: 1747–1757.
   PubMed Web of Science ®Google Scholar
• Chung EJ, Roh MI, Kwon OW, Koh HJ. Effects of macular ischemia on the outcome of intravitreal bevacizumab therapy for diabetic macular edema. Retina 2008; 28: 957–963.
   PubMed Web of Science ®Google Scholar
• Arevalo JF, Sanchez JG, Wu L, Maia M, Alezzandrini AA, Brito M, Bonafonte S et al. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan‐American Collaborative Retina Study Group at 24-months. Ophthalmology 2009; 116: 1488–1497.
   PubMed Web of Science ®Google Scholar
• Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, Gandorfer A et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006; 26: 999–1005.
   PubMed Web of Science ®Google Scholar
• Kook D, Wolf A, Kreutzer T, Neubauer A, Strauss R, Ulbig M, Kampik A et al. Long‐term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. Retina 2008; 28: 1053–1060.
   PubMed Web of Science ®Google Scholar
• Soheilian M, Ramezani A, Bijanzadeh B, Yaseri M, Ahmadieh H, Dehghan MH, Azarmina M et al. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina 2007; 27: 1187–1195.
   PubMed Web of Science ®Google Scholar
• Soheilian M, Ramezani A, Obudi A, Bijanzadeh B, Salehipour M, Yaseri M, Ahmadieh H et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 2009; 116: 1142–1150.
   PubMed Web of Science ®Google Scholar
• Michaelides M, Kaines A, Hamilton RD, Fraser‐bell S, Rajendram R, Quhill F, Boos CJ et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12‐month data: report 2. Ophthalmology 2010; 117: 1078–1086.e2.
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007; 114: 1860–1867.
   PubMed Web of Science ®Google Scholar
• Arevalo JF, Sanchez JG, Fromow‐guerra J, Wu L, Berrocal MH, Farah ME, Cardillo J et al. Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan‐American Collaborative Retina Study Group (PACORES) at 12‐month follow‐up. Graefes Arch Clin Exp Ophthalmol 2009; 247: 735–743.
   PubMed Web of Science ®Google Scholar
• Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, Mitchell P et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12‐month, randomized, controlled, double‐masked, multicenter phase II study. Diabetes Care 2010; 33: 2399–2405.
   PubMed Web of Science ®Google Scholar
• Mitchell P, Bandello F, Schmidt‐erfurth U, Lang GE, Massin P, Schlingemann RO, Sutter F et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118: 615–625.
   PubMed Web of Science ®Google Scholar
• Do DV, Schmidt‐erfurth U, Gonzalez VH, Gordon CM, Tolentino M, Berliner AJ, Vitti R et al. The DA VINCI Study: phase 2 primary results of VEGF Trap‐Eye in patients with diabetic macular edema. Ophthalmology 2011; 118: 1819–1826.
   PubMed Web of Science ®Google Scholar
• Schmucker C, Loke YK, Ehlken C, Agostini HT, Hansen LL, Antes G, Lelgemann M. Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age‐related macular degeneration: a safety review. Br J Ophthalmol 2011; 95: 308–317.
   PubMed Web of Science ®Google Scholar
• Van wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. JAMA 2005; 293: 1509–1513.
   PubMed Web of Science ®Google Scholar
• Storkebaum E, Lambrechts D, Carmeliet P. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays 2004; 26: 943–954.
   PubMed Web of Science ®Google Scholar
• Famiglietti EV, Stopa EG, Mcgookin ED, Song P, Leblanc V, Streeten BW. Immunocytochemical localization of vascular endothelial growth factor in neurons and glial cells of human retina. Brain Res 2003; 969: 195–204.
   PubMed Web of Science ®Google Scholar